Autopsy report · NCT00630994

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

“Stopped due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 1 month before it stopped.
• 4 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Chronic Myeloproliferative Disorders; Secondary Myelofibrosis

Interventions

Dacogen

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
  “Terminated due to slow accrual” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.